A Multi-center, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence

ID Number 12-1154

Principal Investigator(s)
Yvonne Saenger

Department(s) or Division(s)
Hematology and Medical Oncology


The purpose of this study is to confirm the safety of the investigational vaccine POL-103A and test if its administration on a regular schedule can increase the immune system activity, which is thought to delay the melanoma from coming back.

Contact Information
(212) 824-7308
(212) 824-7293

Recruiting Patients: No